NCT03758417: An ongoing trial by Nanjing Legend Biotech Co.
This trial is ongoing. It must report results 6 months, 3 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT03758417 |
|---|---|
| Title | A Phase 2, Open-Label Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA in Chinese Subjects With Relapsed or Refractory Multiple Myeloma |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 23, 2019 |
| Completion date | July 10, 2025 |
| Required reporting date | July 10, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |